Dicot (DICOT) Q3 2025 earnings summary

Executive summary

• Phase 2a clinical study for LIB-01 completed, showing long-lasting improvement in erectile function and favorable safety profile; effect sustained for eight weeks after a three-day treatment.

• Company preparing for Phase 2b study, including tablet development and IND submission to FDA.

• LIB-01 highlighted by Oppenheimer as a promising candidate in the longevity and erectile dysfunction space.

Financial highlights

• Net sales were MSEK 0.0 for both Q3 and the nine-month period, unchanged year-over-year.

• Result after financial items for Q3 was MSEK -16.1 (vs. -10.2 last year); for Jan–Sep, MSEK -63.4 (vs. -37.0 last year).

• Earnings per share for Q3 was SEK -0.01 (unchanged); Jan–Sep was SEK -0.03 (improved from -0.04).

• Operating expenses for Q3 were SEK 16.6 million, up from SEK 10.2 million last year but down from SEK 25.0 million in the previous quarter.

• Cash and cash equivalents at quarter-end were SEK 90.0 million (down from SEK 130.4 million last year).

Outlook and guidance

• Cash balance intended to finance Phase 2b study, manufacturing scale-up, and preparations for Phase 3.

• Additional funding will be needed before Phase 2b, potentially through equity, out-licensing, or both.

• Ongoing evaluation of expanding indications, including metabolic diseases.